BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loffredo L, Pastori D, Farcomeni A, Violi F. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;153:480-487.e1. [PMID: 28479379 DOI: 10.1053/j.gastro.2017.04.042] [Cited by in Crossref: 162] [Cited by in F6Publishing: 124] [Article Influence: 32.4] [Reference Citation Analysis]
Number Citing Articles
1 Violi F, Loffredo L, Pastori D. Anticoagulation in patients with advanced liver disease: an open issue. Intern Emerg Med 2021;16:61-71. [PMID: 33073317 DOI: 10.1007/s11739-020-02526-6] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Cotter TG, Pillai AA. Consult for Portal Vein Thrombosis. Clin Liver Dis (Hoboken) 2019;14:74-7. [PMID: 31508225 DOI: 10.1002/cld.748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Shatzel JJ, O'Donnell M, Olson SR, Kearney MR, Daughety MM, Hum J, Nguyen KP, DeLoughery TG. Venous thrombosis in unusual sites: A practical review for the hematologist. Eur J Haematol 2019;102:53-62. [PMID: 30267448 DOI: 10.1111/ejh.13177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
4 Mohan BP, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis. Ann Gastroenterol 2020;33:521-7. [PMID: 32879600 DOI: 10.20524/aog.2020.0503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Adaramola O, Solomon N, Anyanwu F, Desrosier A, Smith M. Anticoagulation status post radiofrequency ablation in a patient with hepatocellular carcinoma and delayed bleeding event. Radiol Case Rep 2020;15:1381-5. [PMID: 32636978 DOI: 10.1016/j.radcr.2020.05.066] [Reference Citation Analysis]
6 Rank KM, Lake J. CON: Anticoagulation for Portal Vein Thrombosis in Advanced Cirrhosis. Clin Liver Dis (Hoboken) 2018;12:80-2. [PMID: 30988916 DOI: 10.1002/cld.713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Basili S, Pastori D, Raparelli V, Violi F. Anticoagulant therapy in patients with liver cirrhosis and portal vein thrombosis: insights for the clinician. Therap Adv Gastroenterol 2018;11:1756284818793561. [PMID: 30202445 DOI: 10.1177/1756284818793561] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
8 Violi F, Pastori D, Farcomeni A, Loffredo L. Reply. Gastroenterology 2018;154:761-762.e1. [PMID: 29351834 DOI: 10.1053/j.gastro.2018.01.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA Clinical Practice Guideline on the Management of Coagulation Disorders in Patients With Cirrhosis. Gastroenterology 2021;161:1615-1627.e1. [PMID: 34579936 DOI: 10.1053/j.gastro.2021.08.015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis. Int J Hepatol. 2018;2018:8432781. [PMID: 29973997 DOI: 10.1155/2018/8432781] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 9.3] [Reference Citation Analysis]
11 Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations. Can J Gastroenterol Hepatol. 2019;2019:4383269. [PMID: 30792971 DOI: 10.1155/2019/4383269] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Fan X, Huang X, Hershman M, Zheng X, Jiang C, Yue B, Weisberg I. Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. Eur J Gastroenterol Hepatol 2020;32:1160-7. [PMID: 31834054 DOI: 10.1097/MEG.0000000000001624] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Qi X, Valla DC, Guo X. Anticoagulation for Portal Vein Thrombosis in Cirrhosis: Selection of Appropriate Patients. Gastroenterology 2018;154:760-1. [PMID: 29351830 DOI: 10.1053/j.gastro.2017.09.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ghazaleh S, Beran A, Aburayyan K, Nehme C, Patel D, Khader Y, Sharma S, Aziz M, Abdel-Aziz Y, Hammad T, Nawras A. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:104-10. [PMID: 33414629 DOI: 10.20524/aog.2020.0544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Turco L, Schepis F, Villa E. The Role of Anticoagulation in Treating Portal Hypertension. Curr Hepatol Rep 2018;17:200-8. [PMID: 30546994 DOI: 10.1007/s11901-018-0406-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
16 Intagliata NM, Davitkov P, Allen AM, Falck-Ytter YT, Stine JG. AGA Technical Review on Coagulation in Cirrhosis. Gastroenterology 2021;161:1630-56. [PMID: 34579937 DOI: 10.1053/j.gastro.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jiang TT, Luo XP, Sun JM, Gao J. Clinical outcomes of transcatheter selective superior mesenteric artery urokinase infusion therapy vs transjugular intrahepatic portosystemic shunt in patients with cirrhosis and acute portal vein thrombosis. World J Gastroenterol 2017; 23(41): 7470-7477 [PMID: 29151701 DOI: 10.3748/wjg.v23.i41.7470] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
18 Ju C, Li X, Gadani S, Kapoor B, Partovi S. Portal Vein Thrombosis: Diagnosis and Endovascular Management. Rofo 2021. [PMID: 34649289 DOI: 10.1055/a-1642-0990] [Reference Citation Analysis]
19 Valeriani E, Di Nisio M, Riva N, Caiano LM, Porreca E, Bang SM, Beyer-Westendorf J, Sartori MT, Barillari G, Santoro R, Kamphuisen PW, Alatri A, Malato A, Vidili G, Oh D, Schulman S, Ageno W; International Registry on Splanchnic Vein Thrombosis (IRSVT) study group. Clinical history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost 2021;19:983-91. [PMID: 33306241 DOI: 10.1111/jth.15214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
21 Wan YM, Li YH, Wu HM, Xu ZY, Xu Y, Yang LH, Wu XN, Yang JH. Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant). Medicine (Baltimore) 2017;96:e8498. [PMID: 29137043 DOI: 10.1097/MD.0000000000008498] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
22 Liu J, Zhou C, Shi Q, Ma J, Ye T, Zheng C, Feng G, Xiong B. Exploration of interventional therapy strategy for portal vein occlusion: a case series study. Eur J Gastroenterol Hepatol 2020;32:507-16. [PMID: 31658174 DOI: 10.1097/MEG.0000000000001586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
24 Valla DC. Recent developments in the field of vascular liver diseases. Liver Int 2020;40 Suppl 1:142-8. [PMID: 32077611 DOI: 10.1111/liv.14348] [Reference Citation Analysis]
25 Bos I, Blondeau M, Wouters D, Camus C, Houssel-Debry P, van der Plas WS, Nieuwenhuis LM, Bardou-Jacquet E, Lisman T, de Meijer VE, Porte RJ, Rayar M. Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdel-grade I/II portal vein thrombosis: A two-center retrospective study. J Thromb Haemost 2021. [PMID: 34297481 DOI: 10.1111/jth.15472] [Reference Citation Analysis]
26 Noronha Ferreira C, Reis D, Cortez-Pinto H, Tato Marinho R, Gonçalves A, Palma S, Leite I, Rodrigues T, Pedro AJ, Alexandrino P, Serejo F, Sobral Dias M, Ferreira P, Vasconcelos M, Damião F, Xavier Brito L, Baldaia C, Fatela N, Ramalho F, Velosa J. Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis. Dig Dis Sci 2019;64:2671-83. [PMID: 30852769 DOI: 10.1007/s10620-019-05572-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
27 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
28 Chen J, Zhu J, Zhang C, Song Y, Huang P. Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. Eur Radiol 2020;30:2871-80. [PMID: 32020403 DOI: 10.1007/s00330-019-06649-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Qi X, Guo X, Yoshida EM, Méndez-Sánchez N, De Stefano V, Tacke F, Mancuso A, Sugawara Y, Yang SS, Teschke R, Arora A, Valla DC. Transient portal vein thrombosis in liver cirrhosis. BMC Med 2018;16:83. [PMID: 29871683 DOI: 10.1186/s12916-018-1069-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
30 Søgaard KK, Adelborg K, Darvalics B, Horváth-Puhó E, Beyer-Westendorf J, Ageno W, Sørensen HT. Risk of bleeding and arterial cardiovascular events in patients with splanchnic vein thrombosis in Denmark: a population-based cohort study. Lancet Haematol 2018;5:e441-9. [PMID: 30201587 DOI: 10.1016/S2352-3026(18)30133-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
31 Senzolo M, Piano S, Shalaby S, Tonon M, Tonello S, Zanetto A, Sacerdoti D, Simioni P, Bombonato G, Burra P, Angeli P. Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis. Am J Med 2021:S0002-9343(21)00389-2. [PMID: 34197784 DOI: 10.1016/j.amjmed.2021.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Riva N, Ageno W. Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. J Transl Int Med 2018;6:6-10. [PMID: 29607297 DOI: 10.2478/jtim-2018-0002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Lisman T. Crosslinked clots formed independently of factor XIII and without fibrinogen-to-fibrin conversion - is this a liver-specific phenomenon? J Thromb Haemost 2019;17:110-2. [PMID: 30412653 DOI: 10.1111/jth.14328] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Ronca V, Podda GM, Cattaneo M. An "unmodifiable" risk factor that has been modified. Intern Emerg Med 2021;16:157-9. [PMID: 31396923 DOI: 10.1007/s11739-019-02170-9] [Reference Citation Analysis]
35 Noronha Ferreira C, Cortez‐pinto H, Serejo F, Velosa J, Marinho RT. Anticoagulation in patients with cirrhosis and portal vein thrombosis: Safety and beneficial effect on OLT‐free survival. Liver Int 2019;39:2002-2002. [DOI: 10.1111/liv.14231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Fortea JI, Carrera IG, Puente Á, Cuadrado A, Huelin P, Tato CÁ, Fernández PÁ, Montes MDRP, Céspedes JN, López AB, Sanchez FJG, Hoyos ML, Crespo J, Fábrega E. Portal Thrombosis in Cirrhosis: Role of Thrombophilic Disorders. J Clin Med 2020;9:E2822. [PMID: 32878264 DOI: 10.3390/jcm9092822] [Reference Citation Analysis]
37 Sack JS, Li M, Zucker SD. Bleeding Outcomes Following Transesophageal Echocardiography in Patients With Cirrhosis and Esophageal Varices. Hepatol Commun 2021;5:283-92. [PMID: 33553975 DOI: 10.1002/hep4.1635] [Reference Citation Analysis]
38 Mazzarelli C, Vangeli M, Airoldi A. Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. Clinical Gastroenterology and Hepatology 2019;17:797-8. [DOI: 10.1016/j.cgh.2018.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
39 Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. [PMID: 34217184 DOI: 10.51821/84.2.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Mantaka A, Augoustaki A, Kouroumalis EA, Samonakis DN. Portal vein thrombosis in cirrhosis: diagnosis, natural history, and therapeutic challenges. Ann Gastroenterol 2018;31:315-29. [PMID: 29720857 DOI: 10.20524/aog.2018.0245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
41 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res 2018;170:102-8. [PMID: 30153564 DOI: 10.1016/j.thromres.2018.08.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
42 Dillon A, Egan K, Kevane B, Galvin Z, Maguire P, Ní Áinle F, Stewart S. Liver stiffness and thrombin generation in compensated cirrhosis. Res Pract Thromb Haemost 2019;3:291-7. [PMID: 31011714 DOI: 10.1002/rth2.12173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
43 Valeriani E, Di Nisio M, Riva N, Cohen O, Porreca E, Senzolo M, De Gottardi A, Magaz M, Garcia-Pagan JC, Ageno W. Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Thromb Haemost 2021;121:867-76. [PMID: 33525037 DOI: 10.1055/s-0040-1722192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
44 Zhan C, Prabhu V, Kang SK, Li C, Zhu Y, Kim S, Olsen S, Jacobson IM, Dagher NN, Carney B, Hickey RM, Taslakian B. Comparison of Non-Tumoral Portal Vein Thrombosis Management in Cirrhotic Patients: TIPS Versus Anticoagulation Versus No Treatment. J Clin Med 2021;10:2316. [PMID: 34073236 DOI: 10.3390/jcm10112316] [Reference Citation Analysis]
45 Kwon J, Koh Y, Yu SJ, Yoon J. Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. Thrombosis Research 2018;163:71-6. [DOI: 10.1016/j.thromres.2018.01.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
46 Huang YK, Li YJ, Li B, Wang P, Wang QH. Dysregulated liver function in SARS-CoV-2 infection: Current understanding and perspectives. World J Gastroenterol 2021; 27(27): 4358-4370 [PMID: 34366609 DOI: 10.3748/wjg.v27.i27.4358] [Reference Citation Analysis]
47 Caldwell S, Carlini LE. Coagulation Homeostasis in Liver Disease. Clin Liver Dis (Hoboken) 2020;16:137-41. [PMID: 33163164 DOI: 10.1002/cld.935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Bianchini M, Cavani G, Bonaccorso A, Turco L, Vizzutti F, Sartini A, Gitto S, Merighi A, Banchelli F, Villa E, Schepis F. Low molecular weight heparin does not increase bleeding and mortality post-endoscopic variceal band ligation in cirrhotic patients. Liver Int 2018;38:1253-62. [DOI: 10.1111/liv.13728] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
49 Zheng K, Yoshida EM, Tacke F, Li Y, Guo X, Qi X. Risk of Stroke in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Clinical Gastroenterology 2020;54:96-105. [DOI: 10.1097/mcg.0000000000001201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
50 Wilke TJ, Fremming BA, Brown BA, Markin NW, Kassel CA. 2020 Clinical Update in Liver Transplantation. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00100-2. [PMID: 33653578 DOI: 10.1053/j.jvca.2021.02.005] [Reference Citation Analysis]
51 Stotts MJ, Lisman T, Intagliata NM. The Spectrum of Disease Severity in Cirrhosis and Its Implications for Hemostasis. Semin Thromb Hemost 2020;46:716-23. [PMID: 32820482 DOI: 10.1055/s-0040-1715449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
53 McMurry HS, Jou J, Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur J Haematol 2021. [PMID: 34258797 DOI: 10.1111/ejh.13688] [Reference Citation Analysis]
54 Lisman T, Bos S, Intagliata NM. Mechanisms of enhanced thrombin‐generating capacity in patients with cirrhosis. J Thromb Haemost 2018;16:1128-31. [DOI: 10.1111/jth.14020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
55 Stravitz RT. Algorithms for managing coagulation disorders in liver disease. Hepatol Int 2018;12:390-401. [PMID: 30066204 DOI: 10.1007/s12072-018-9886-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
56 Summers KL, Davis KA, Nisly SA. Bleeding Risk of Therapeutic Unfractionated Heparin and Low Molecular Weight Heparin in Patients with Cirrhosis. Clin Drug Investig 2020;40:191-6. [PMID: 31755014 DOI: 10.1007/s40261-019-00875-5] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
57 Wang CY, Wei LQ, Niu HZ, Gao WQ, Wang T, Chen SJ. Agitation thrombolysis combined with catheter-directed thrombolysis for the treatment of non-cirrhotic acute portal vein thrombosis. World J Gastroenterol 2018; 24(39): 4482-4488 [PMID: 30357003 DOI: 10.3748/wjg.v24.i39.4482] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
58 Faccia M, Ainora ME, Ponziani FR, Riccardi L, Garcovich M, Gasbarrini A, Pompili M, Zocco MA. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J Gastroenterol 2019; 25(31): 4437-4451 [PMID: 31496623 DOI: 10.3748/wjg.v25.i31.4437] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
59 Niu XK, Das SK, Wu HL, Chen Y. Computed tomography-based score model/nomogram for predicting technical and midterm outcomes in transjugular intrahepatic portosystemic shunt treatment for symptomatic portal cavernoma. World J Clin Cases 2020; 8(5): 887-899 [PMID: 32190625 DOI: 10.12998/wjcc.v8.i5.887] [Reference Citation Analysis]
60 Stotts MJ, Wentworth BJ, Northup PG. Management of Portal Vein Thrombosis in Cirrhosis. Semin Liver Dis 2021;41:79-86. [PMID: 33764487 DOI: 10.1055/s-0040-1722260] [Reference Citation Analysis]
61 Naymagon L. Venous thrombosis of the liver: current and emerging concepts in management. Transl Res 2020;225:54-69. [PMID: 32407789 DOI: 10.1016/j.trsl.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
62 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020;115:18-40. [PMID: 31895720 DOI: 10.14309/ajg.0000000000000486] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
64 Mannucci PM, Tripodi A. Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. Vascul Pharmacol 2019;113:92-3. [PMID: 29890295 DOI: 10.1016/j.vph.2018.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
65 Proietti M, Marzona I, Vannini T, Colacioppo P, Tettamanti M, Foresta A, Fortino I, Merlino L, Lip GYH, Roncaglioni MC. Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. Eur Heart J Cardiovasc Pharmacother 2021;7:f84-92. [PMID: 32129845 DOI: 10.1093/ehjcvp/pvaa015] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
66 Wang J, Chai JS, Zhang YM. Anticoagulation treatment of portal vein thrombosis in a patient with cirrhosis awaiting liver transplantation: A case report. Medicine (Baltimore) 2018;97:e11183. [PMID: 29952969 DOI: 10.1097/MD.0000000000011183] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Koh JH, Liew ZH, Ng GK, Liu HT, Tam YC, De Gottardi A, Wong YJ. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00408-4. [PMID: 34393072 DOI: 10.1016/j.dld.2021.07.039] [Reference Citation Analysis]
68 Zhang L, Huan H, Tong H, Wei B, Wang Z, Liu C, Wu H. Warfarin prevented de novo portal vein thrombosis after transjugular intrahepatic portosystemic shunt: A retrospective study. Medicine (Baltimore) 2020;99:e18737. [PMID: 31914090 DOI: 10.1097/MD.0000000000018737] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Sen I, Yohanathan L, Kärkkäinen JM, Nagorney DM. Current Indications and Long-Term Outcomes of Surgical Portosystemic Shunts in Adults. J Gastrointest Surg 2021;25:1437-44. [PMID: 32424687 DOI: 10.1007/s11605-020-04643-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
70 Bhangui P, Lim C, Levesque E, Salloum C, Lahat E, Feray C, Azoulay D. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. J Hepatol. 2019;71:1038-1050. [PMID: 31442476 DOI: 10.1016/j.jhep.2019.08.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
71 Wood CP, Rowe IA. What Are the Benefits of Anticoagulation for Portal Vein Thrombosis in Individuals With Cirrhosis? Gastroenterology 2018;154:759-60. [PMID: 29352956 DOI: 10.1053/j.gastro.2017.08.075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
72 van den Boom BP, von Meijenfeldt FA, Adelmeijer J, Roberts LN, Bernal W, Lisman T. Heparins have adequate ex vivo anticoagulant effects in hospitalized patients with cirrhosis. J Thromb Haemost 2021;19:1472-82. [PMID: 33725411 DOI: 10.1111/jth.15296] [Reference Citation Analysis]
73 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Zhou T, Sun X, Zhou T, Li Y, Chen X, Cheng B, Gao Y. Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00228. [PMID: 32858573 DOI: 10.14309/ctg.0000000000000228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
75 Abergel A, Gasperment M, Nery FG, Buchard B, Lebreton A, Hordonneau C, Duron C, Valla D, Sophie H, Ledain-Rautou E, Hernandez-Gea V, Dutheil D, Plessier A, Bureau C, Francoz C. Extrahepatic portal vein obstruction (EHPVO) in cirrhosis. Clin Res Hepatol Gastroenterol 2020;44:497-502. [PMID: 32312599 DOI: 10.1016/j.clinre.2020.03.014] [Reference Citation Analysis]
76 Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. [PMID: 33219529 DOI: 10.1002/hep.31646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
77 Violi F, Vestri A, Menichelli D, Di Rocco A, Pastori D, Pignatelli P. Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Advanced Liver Disease: An Exploratory Meta-Analysis. Hepatol Commun 2020;4:1034-40. [PMID: 32626835 DOI: 10.1002/hep4.1513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
78 Gîrleanu I, Trifan A, Stanciu C, Sfarti C. Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture. World J Gastroenterol 2018; 24(39): 4419-4427 [PMID: 30356984 DOI: 10.3748/wjg.v24.i39.4419] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
79 Senzolo M, Riva N, Dentali F, Rodriguez-Castro K, Sartori MT, Bang SM, Martinelli I, Schulman S, Alatri A, Beyer-Westendorf J, Di Minno MND, Ageno W; IRSVT study investigators. Long-Term Outcome of Splanchnic Vein Thrombosis in Cirrhosis. Clin Transl Gastroenterol. 2018;9:176. [PMID: 30108204 DOI: 10.1038/s41424-018-0043-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
80 Marjot T, Webb GJ, Barritt AS 4th, Moon AM, Stamataki Z, Wong VW, Barnes E. COVID-19 and liver disease: mechanistic and clinical perspectives. Nat Rev Gastroenterol Hepatol 2021;18:348-64. [PMID: 33692570 DOI: 10.1038/s41575-021-00426-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
81 Ding H, Zhang Y, Zhao L, Wu S, Liu J, Wang C, Pei T, Su Y. What intervention regimen is most effective prevention for Portal venous system thrombosis after splenectomy in cirrhotics patients with Portal hypertension? Systematic review and network meta-analysis. Pharmacological Research 2020;157:104825. [DOI: 10.1016/j.phrs.2020.104825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Ponthus S, Spahr L, Casini A, Berney T, Frossard J, Majno P, Elkrief L. Safety of variceal band ligation in patients with cirrhosis and portal vein thrombosis treated with anticoagulant therapy: A retrospective study. European Journal of Gastroenterology & Hepatology 2020;32:395-400. [DOI: 10.1097/meg.0000000000001522] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
84 Gîrleanu I, Trifan A, Sfarti C. Splanchnic Vein Thrombosis in Cirrhosis - Areas Still in the Shadow. Clin Transl Gastroenterol 2018;9:211. [PMID: 30523247 DOI: 10.1038/s41424-018-0079-3] [Reference Citation Analysis]
85 Ai MH, Dong WG, Tan XP, Xu L, Xu C, Zhang Q, Zhang Y, Li J. Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2020;32:1395-400. [PMID: 32675774 DOI: 10.1097/MEG.0000000000001846] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
86 Nicoară-Farcău O, Soy G, Magaz M, Baiges A, Turon F, Garcia-Criado A, Barrufet M, Burrel M, Hernández-Gea V, García-Pagán JC. New Insights into the Pathogenesis, Risk Factors, and Treatment of Portal Vein Thrombosis in Patients with Cirrhosis. Semin Thromb Hemost 2020;46:673-81. [PMID: 32820481 DOI: 10.1055/s-0040-1715473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
87 Lamarche MC, Alrajhi E, Wells PS. Direct oral anticoagulant use in special populations. Curr Opin Pulm Med 2021;27:311-8. [PMID: 34115699 DOI: 10.1097/MCP.0000000000000787] [Reference Citation Analysis]
88 Xu XY, Ding HG, Li WG, Xu JH, Han Y, Jia JD, Wei L, Duan ZP, Ling-Hu EQ, Zhuang H. Chinese guidelines on the management of liver cirrhosis (abbreviated version) . World J Gastroenterol 2020; 26(45): 7088-7103 [PMID: 33362370 DOI: 10.3748/wjg.v26.i45.7088] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
89 Suda T, Takatori H, Hayashi T, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Yamashita T, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Kaneko S. Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. Life (Basel) 2020;10:E177. [PMID: 32899804 DOI: 10.3390/life10090177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Mancuso A. Portal vein thrombosis in cirrhosis: the issue of treatment. Hepatology 2021. [PMID: 34709653 DOI: 10.1002/hep.32216] [Reference Citation Analysis]
91 Wu WY, Kong DR. Advances in diagnosis and treatment of portal venous thrombosis. Shijie Huaren Xiaohua Zazhi 2021; 29(4): 165-173 [DOI: 10.11569/wcjd.v29.i4.165] [Reference Citation Analysis]
92 Meijenfeldt FAV, Jenne CN. Netting Liver Disease: Neutrophil Extracellular Traps in the Initiation and Exacerbation of Liver Pathology. Semin Thromb Hemost 2020;46:724-34. [PMID: 32906176 DOI: 10.1055/s-0040-1715474] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Zanetto A, Garcia-Tsao G. Some Answers and More Questions About Portal Vein Thrombosis in Patients With Decompensated Cirrhosis. Clin Gastroenterol Hepatol 2020;18:2432-4. [PMID: 32302710 DOI: 10.1016/j.cgh.2020.04.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
94 Lopez-Gomez M, Llop E, Puente A, Hernández Conde M, Ruiz P, Alvárez S, Martínez JL, Abad J, Fernández N, Perelló C, Fernández-Carrillo C, Ferre C, Trapero M, Fraga E, Crespo J, Calleja Panero JL. Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: Incidence and risk factors. Hepatol Res 2021. [PMID: 34324766 DOI: 10.1111/hepr.13703] [Reference Citation Analysis]
95 Tomita K, Chiba N, Ochiai S, Yokozuka K, Gunji T, Hikita K, Ozawa Y, Okihara M, Sano T, Tsutsui R, Kawachi S. Successful Treatment of Acute Superior Mesenteric Vein Thrombosis Caused by Infection Using the Ileocolic Vein as an Approach Site for Thrombectomy. The American Surgeon 2018;84:558-60. [DOI: 10.1177/000313481808401221] [Reference Citation Analysis]
96 Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis (2020, Shanghai). J Dig Dis 2021;22:176-86. [PMID: 33470535 DOI: 10.1111/1751-2980.12970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
97 Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. Eur J Gastroenterol Hepatol 2021;33:911-6. [PMID: 33079786 DOI: 10.1097/MEG.0000000000001958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
98 Turon F, Hernández-Gea V, García-Pagán JC. Portal vein thrombosis: yes or no on anticoagulation therapy. Curr Opin Organ Transplant 2018;23:250-6. [PMID: 29432256 DOI: 10.1097/MOT.0000000000000506] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
99 Lu J, Zhang X, Zhong B, Lau WY, Madoff DC, Davidson JC, Qi X, Cheng S, Teng G. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. The Lancet Gastroenterology & Hepatology 2019;4:721-30. [DOI: 10.1016/s2468-1253(19)30178-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 9.3] [Reference Citation Analysis]
100 Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1:227-39. [PMID: 32039373 DOI: 10.1016/j.jhepr.2019.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
101 Mauro E, Gadano A. What's new in portal hypertension? Liver Int 2020;40 Suppl 1:122-7. [PMID: 32077610 DOI: 10.1111/liv.14366] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
102 Sasaki K, Mcvey JC, Firl DJ, Andreatos N, Moro A, Coromina Hernandez L, Matsushima H, Teresa DU, Fujiki M, Aucejo FN, Quintini C, Kwon CD, Eghtesad B, Miller CM, Hashimoto K. Sufficient hepatic artery flow compensates for poor portal vein flow after liver transplantation in patients with portal vein thrombosis. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
103 Wang M, Ding L, Xu M, Xie J, Wu S, Xu S, Yao Y, Liu Q. A novel method detecting the key clinic factors of portal vein system thrombosis of splenectomy & cardia devascularization patients for cirrhosis & portal hypertension. BMC Bioinformatics. 2019;20:720. [PMID: 31888439 DOI: 10.1186/s12859-019-3233-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
104 Pastori D, Lip GYH, Farcomeni A, Del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F; ATHERO-AF study group. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. Int J Cardiol. 2018;264:58-63. [PMID: 29776574 DOI: 10.1016/j.ijcard.2018.01.097] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 13.7] [Reference Citation Analysis]
105 Mancuso A, Politi F, Maringhini A. Portal Vein Thromboses in Cirrhosis: To Treat or Not to Treat? Gastroenterology 2018;154:758. [PMID: 29352958 DOI: 10.1053/j.gastro.2017.07.053] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
106 Bergère M, Erard-poinsot D, Boillot O, Valette P, Guillaud O, Chambon-augoyard C, Dumortier J. Portal vein thrombosis and liver cirrhosis: Long-term anticoagulation is effective and safe. Clinics and Research in Hepatology and Gastroenterology 2019;43:395-402. [DOI: 10.1016/j.clinre.2018.11.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
107 Yoshida H, Shimizu T, Yoshioka M, Taniai N. Management of portal hypertension based on portal hemodynamics. Hepatol Res 2021;51:251-62. [PMID: 33616258 DOI: 10.1111/hepr.13614] [Reference Citation Analysis]
108 Williams C, Stewart E, Conzen KD, Wolf S, Tran TT. Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. Semin Cardiothorac Vasc Anesth 2021;25:200-7. [DOI: 10.1177/1089253220982183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Acuna-villaorduna A, Tran V, Gonzalez-lugo JD, Azimi-nekoo E, Billett HH. Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: A retrospective cohort study. Thrombosis Research 2019;174:137-40. [DOI: 10.1016/j.thromres.2018.12.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
110 Lv Y, Bai W, Li K, Wang Z, Guo W, Luo B, Wang J, Wang Q, Wang E, Xia D, Li X, Yuan J, Han N, Niu J, Yin Z, Fan D, Han G. Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study. Am J Gastroenterol 2021;116:1447-64. [PMID: 33630766 DOI: 10.14309/ajg.0000000000001194] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
111 Dong S, Qi H, Li Y, Men P, Alifu M, Zhang Y, Li Y, Zhao R. A systematic review and meta-analysis of anticoagulation therapy for portal vein thrombosis in patients with cirrhosis: to treat or not to treat? Hepatol Int 2021. [PMID: 34487316 DOI: 10.1007/s12072-021-10233-3] [Reference Citation Analysis]
112 Tacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein WO, Berg T; Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), vertreten durch Frank Tacke, Markus Cornberg, Martina Sterneck, Jonel Trebicka, Thomas Berg., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), vertreten durch Wolf Bechstein., Deutsche Transplantationsgesellschaft (DTG), vertreten durch Utz Settmacher., Die Leitlinie wird von der Deutschen Gesellschaft für Pneumologie (DGP) unterstützt. S1-Leitlinie zur Versorgung von Lebertransplantierten während der COVID-19-Pandemie – AWMF-Register Nr. 021-031 – Stand: 07.01.21. Z Gastroenterol 2021;59:345-59. [PMID: 33845500 DOI: 10.1055/a-1372-5595] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
113 Alzubaidi S, Patel I, Saini A, Knuttinen G, Naidu S, Kriegshuaser S, Albadawi H, Oklu R. Current concepts in portal vein thrombosis: etiology, clinical presentation and management. Abdom Radiol 2019;44:3453-62. [DOI: 10.1007/s00261-019-02174-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Iida H, Miyake T, Tani M, Tanaka T, Kawakami K, Ikuno Y, Mandai R, Shimizu T. Cerebellar hemorrhage in patients treated with edoxaban for portal vein thrombosis after hepatobiliary surgery: a report of two cases. Surg Case Rep 2020;6:319. [PMID: 33305345 DOI: 10.1186/s40792-020-01086-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Xu X, Xu S, Primignani M, De Stefano V, He Y, Yi F, Guo X, Valla D, Qi X. Nonselective β-Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. Adv Ther 2020;37:1452-63. [PMID: 32076942 DOI: 10.1007/s12325-020-01250-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
117 Yeoh SW, Kok HK. Transjugular intrahepatic portosystemic shunts in portal vein thrombosis: A review. J Dig Dis 2021. [PMID: 34323378 DOI: 10.1111/1751-2980.13035] [Reference Citation Analysis]
118 Artaza T, Lopes M, Romero M, Gómez AZ, de la Cruz G, Sánchez JJ, González C, Gómez R. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis. Gastroenterol Hepatol 2018;41:611-7. [PMID: 30049580 DOI: 10.1016/j.gastrohep.2018.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
119 Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156: 1582-1599. e1. [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 26.3] [Reference Citation Analysis]
120 Xu X, Guo X, Wang R, Wang L, Li Q, Yi F, Li H, Qi X. Low-molecular-weight heparin followed by rivaroxaban for acute occlusive portomesenteric vein thrombosis in a cirrhotic patient treated with multiple endoscopic variceal procedures. Annals of Hepatology 2020;19:573-7. [DOI: 10.1016/j.aohep.2019.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Chen H, Lv Y, Han G. Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the Portal Vein. Gastroenterology 2018;154:758-9. [PMID: 29351835 DOI: 10.1053/j.gastro.2017.08.076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
122 Jepsen P, Tapper EB, Deleuran T, Kazankov K, Askgaard G, Sørensen HT, Vilstrup H, West J. Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study. Hepatology 2021. [PMID: 34137045 DOI: 10.1002/hep.32019] [Reference Citation Analysis]
123 Valla DC, Cazals-Hatem D. Vascular liver diseases on the clinical side: definitions and diagnosis, new concepts. Virchows Arch. 2018;473:3-13. [PMID: 29572606 DOI: 10.1007/s00428-018-2331-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
124 Mei XC, Wang X, Kong DR. IgG4-related autoimmune pancreatitis combined with splenic vein thrombosis leading to variceal bleeding of the fundus: A case report. Shijie Huaren Xiaohua Zazhi 2019; 27(15): 967-971 [DOI: 10.11569/wcjd.v27.i15.967] [Reference Citation Analysis]
125 Zhou JB, Luo BY, Liu CW, Zhu F. Effects of early antiplatelet therapy after splenectomy with gastro-oesophageal devascularization. ANZ J Surg 2018;88:E725-9. [PMID: 29396900 DOI: 10.1111/ans.14395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Riva N, Ageno W. Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. J Clin Med 2020;9:E743. [PMID: 32164214 DOI: 10.3390/jcm9030743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
127 Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021;75:442-53. [PMID: 33930474 DOI: 10.1016/j.jhep.2021.04.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
128 Zhang R, Huang X, Jiang Y, Wang J, Chen S. Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2020;2020:8887574. [PMID: 33381477 DOI: 10.1155/2020/8887574] [Reference Citation Analysis]
129 Bert J, Geerts A, Vanlander A, Abreu de Carvalho L, Degroote H, Berrevoet F, Rogiers X, van Vlierberghe H, Verhelst X. Up to 50% of portal vein thrombosis remains undiagnosed until liver transplantation. Clin Transplant 2020;34:e14107. [PMID: 33030231 DOI: 10.1111/ctr.14107] [Reference Citation Analysis]
130 O’leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019;157:34-43.e1. [DOI: 10.1053/j.gastro.2019.03.070] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 27.0] [Reference Citation Analysis]
131 Yeo JW, Law MSN, Lim JCL, Ng CH, Tan DJH, Tay PWL, Syn N, Tham HY, Huang DQ, Siddiqui MS, Iyer S, Muthiah M. Meta-analysis and systematic review: Prevalence, graft failure, mortality, and post-operative thrombosis in liver transplant recipients with pre-operative portal vein thrombosis. Clin Transplant 2021;:e14520. [PMID: 34687558 DOI: 10.1111/ctr.14520] [Reference Citation Analysis]
132 Xu X, Guo X, De Stefano V, Silva-Junior G, Goyal H, Bai Z, Zhao Q, Qi X. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol Int 2019;13:468-81. [PMID: 31175581 DOI: 10.1007/s12072-019-09951-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
133 Pettinari I, Vukotic R, Stefanescu H, Pecorelli A, Morelli M, Grigoras C, Sparchez Z, Andreone P, Piscaglia F; BO-LIVES (BOlogna LIVEr vascular Studies). Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. Am J Gastroenterol. 2019;114:258-266. [PMID: 30538290 DOI: 10.1038/s41395-018-0421-0] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 14.7] [Reference Citation Analysis]
134 Duceppe E, Lauzon JF, Galliger S, Zhang B, Solomon H, Serrano PE. Incidence and predictors of splanchnic vein thrombosis and mortality following hepatobiliary and pancreatic surgery. J Thromb Haemost 2021;19:797-804. [PMID: 33249718 DOI: 10.1111/jth.15198] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Ogawa S, Yamamoto A, Jogo A, Nakano MM, Kageyama K, Sohgawa E, Nishida N, Kaminou T, Miki Y. Splenic Vein Diameter is a Risk Factor for the Portal Venous System Thrombosis After Partial Splenic Artery Embolization. Cardiovasc Intervent Radiol 2021;44:921-30. [PMID: 33474605 DOI: 10.1007/s00270-020-02751-8] [Reference Citation Analysis]
136 Zanetto A, Barbiero G, Battistel M, Sciarrone SS, Shalaby S, Pellone M, Battistella S, Gambato M, Germani G, Russo FP, Burra P, Senzolo M. Management of portal hypertension severe complications. Minerva Gastroenterol (Torino) 2021;67:26-37. [PMID: 33140623 DOI: 10.23736/S2724-5985.20.02784-1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Serper M, Weinberg EM, Cohen JB, Reese PP, Taddei TH, Kaplan DE. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology 2021;73:219-32. [PMID: 32267547 DOI: 10.1002/hep.31264] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
138 Yang LS, Alukaidey S, Croucher K, Dowling D. Suboptimal use of pharmacological venous thromboembolism prophylaxis in cirrhotic patients. Intern Med J 2018;48:1056-63. [PMID: 29468795 DOI: 10.1111/imj.13766] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
139 Ng CH, Tan DJH, Nistala KRY, Syn N, Xiao J, Tan EXX, Woo FZ, Chew NWS, Huang DQ, Dan YY, Sanyal AJ, Muthiah MD. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. Hepatol Int 2021;15:1196-206. [PMID: 34417718 DOI: 10.1007/s12072-021-10247-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
140 Guillaume M, Bureau C, Plessier A. Is there evidence for stopping anticoagulation therapy before endoscopic variceal ligation? Liver Int 2018;38:1175-6. [PMID: 29932511 DOI: 10.1111/liv.13749] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Zhang L, Hu B, Li W, Huang P, Zhang S, Zhong B, Ni C. 125I Irradiation Stent for Hepatocellular Carcinoma with Main Portal Vein Tumor Thrombosis: A Systematic Review. Cardiovasc Intervent Radiol 2020;43:196-203. [DOI: 10.1007/s00270-019-02346-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
142 Abbattista M, Capecchi M, Martinelli I. Treatment of unusual thrombotic manifestations. Blood 2020;135:326-34. [PMID: 31917405 DOI: 10.1182/blood.2019000918] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]